Compare Abeona Therapeutics Inc (ABEO) vs DoorDash Inc (DASH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs DoorDash Inc — how do they compare? Abeona Therapeutics Inc trades at $6.68 (market cap $373.32M), while DoorDash Inc trades at $185.22 (market cap $85.28B). The key difference: DoorDash Inc is far larger — about 228.4× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, DoorDash Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | DASH | |
|---|---|---|
Market Cap | $373.32M | $85.28B |
Sector | Health | Consumer Cyclical |
52-Week High | $7.23 | $281.74 |
52-Week Low | $4.17 | $146.60 |
Enterprise Value | $228.22M | $83.03B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
DoorDash (DASH) trades at $195.72, up 1.93% today, with a bullish technical signal and strong analyst consensus. Revenue grew to $13.72B in 2025, with net income reaching $935M, though recent quarters show mixed earnings performance. The stock is near resistance at $200, with RSI indicating overbought conditions. Recent news highlights AI initiatives and market dominance.
Outlook remains positive with a $231.50 consensus price target, but risks include competition and high valuation multiples. Earnings growth and international expansion are key catalysts, while inflation and execution challenges pose headwinds for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About DoorDash Inc
Founded in 2013 and headquartered in San Francisco, DoorDash is an online food order demand aggregator. Consumers can use its app to order food on-demand for pickup or delivery from merchants mainly in the U.S. The firm provides a marketplace for the merchants to create a presence online, market their offerings, and meet demand by making the offerings available for pickup or delivery. The firm provides similar service to businesses in addition to restaurants, such as grocery, retail, pet supplies, and flowers. At the end of 2020, DoorDash had over 450,000 merchants, 20 million consumers, and over 1 million dashers on its platform. In 2020, the firm generated $24.7 billion in gross order volume (up 207% year over year) and $2.9 billion in revenue (up 226%).
Read more on DASH →
